Suggested Remit: To appraise the clinical and cost effectiveness of tebentafusp within its marketing authorisation for treating advanced uveal melanoma.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
TA
|
| ID number |
1441
|
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors |
Immunocore |
| Others |
Department for Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
OcuMel |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Melanoma Focus |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Bristol-Myers Squibb Pharmaceuticals |
| |
MSD |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
BNF |
| |
Department of Health, Social Services and Public Safety - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
26 November 2024 - 17 December 2024
|
Final draft guidance |
|
13 March 2024
|
Following the appeal decision, we are conducting further work on this appraisal. An additional appraisal committee meeting will be scheduled in due course. |
|
12 December 2023
|
Appeal decision |
|
15 September 2023
|
Appeal |
|
15 August 2023 - 24 August 2023
|
Final draft guidance |
|
04 July 2023
|
Committee meeting: 2 |
|
18 May 2023
|
The next appraisal committee meeting has been scheduled for 4 July 2023. |
|
27 January 2023
|
The company has been given an extension to the deadline for responding to the appraisal consultation document to allow it to submit further data. The second committee meeting for this appraisal is to be confirmed. |
|
21 June 2022 - 12 July 2022
|
Draft guidance |
|
10 May 2022
|
Committee meeting: 1 |
|
31 August 2021
|
Invitation to participate |
|
29 July 2021 (14:00)
|
Scoping workshop |
|
15 June 2021 - 13 July 2021
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
12 February 2021
|
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of tebentafusp (IMCgp100) for treating metastatic or unresectable HLA-A*02:01 positive uveal melanoma.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
For information, we anticipate that the appraisal will now begin during late August 2021 when we will write to you about how you can get involved.
|
|
29 October 2020
|
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of tebentafusp (IMCgp100) for treating metastatic HLA-A*02:01 positive uveal melanoma.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
For information, we anticipate that the appraisal will now begin during mid-June 2021 when we will write to you about how you can get involved.
|
|
16 April 2020
|
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma.
Please note that following on from advice received from the company this appraisal has been rescheduled into the work programme
For information, we anticipate that the appraisal will begin during mid-November 2020 when we will write to you about how you can get involved.
|
|
03 April 2019
|
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
|
27 November 2018
|
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of IMCgp100 for treating metastatic uveal melanoma. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal.
On receiving updated regulatory timing information from the company that is developing IMCgp100, NICE has agreed that a scoping exercise at this time would not be appropriate. Consequently the consultation on the draft scope will be closed and scoping workshop arranged for the 21 January 2019 will be cancelled. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.
If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar at michelle.adhemar@nice.org.uk
|
|
31 July 2017
|
In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual